MaxCyte (NASDAQ: MXCT) — Perfil da empresa, notícias e dados financeiros
MaxCyte specializes in cell engineering tools to support the development of cell therapies and biotherapeutics globally.
MaxCyte
MaxCyte (NASDAQ:MXCT) specializes in cell engineering, providing essential tools and technologies that support the development and commercialization of cellular therapies and biotherapeutics. The company's cutting-edge Flow Electroporation technology and instruments facilitate the discovery, development, and manufacture of new therapies, particularly in the field of immune-oncology, cell therapy, and gene editing. MaxCyte aims to accelerate the fight against a wide range of diseases, including cancer, inherited diseases, and infectious diseases, by empowering researchers and pharmaceutical companies to unlock the full potential of their cell-based research. Serving a global clientele, MaxCyte is committed to innovation and excellence in supporting the advancement of science and medicine.
Resumo
Operações
Produtos e/ou serviços de MaxCyte
- Flow Electroporation Technology - A platform facilitating high-performance cell engineering for research, bioprocessing, and therapeutic applications.
- ExPERT instrument family - Includes ATx, STx, and GTx models tailored for advanced gene editing, cell therapy development, and protein expression optimization.
- CARMA Platform - Utilizing mRNA-based cell therapies for developing treatments against solid tumors and other diseases through a proprietary cell therapy platform.
- Life Sciences Research Instruments - Offering high-quality instruments and tools for cellular engineering, including electroporation buffers and accessories.
- Clinical and Commercial Licensing - Provides partners with access to its technology for development of cell-based therapies, including several partnerships with leading pharmaceutical companies.
- Cell Engineering Services - Custom service offerings to support the development and optimization of cell-based therapies, including process development and training.
equipe executiva do MaxCyte
- Maher MasoudPresident, CEO & Executive Director
- Parmeet AhujaChief Financial Officer
- Jay GelfmanChief Operations Officer
- Ana-Paula Martins FernandesSenior Vice President of Global Sales
- Sidharth KapileshwarChief Corporate Development Officer
- Jill MayerSenior Vice President of Human Resources
Principais indicadores financeiros
Resultados divulgados pela MaxCyte, em USD.
- Cap. de mercado
- 158,9 mi
- Receita (TTM)
- 31,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- -114.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 33 mi | -45,3 mi | -44,6 mi | |
| 38,6 mi | -51,2 mi | -41,1 mi | |
| 41,3 mi | -48,3 mi | -37,9 mi | |
| 44,3 mi | -27,4 mi | -23,6 mi |